Microplastics Move into the Federal Policy Pipeline: What Plastics and Chemicals Companies Need to Know Now

On April 2, 2026, the U.S. Environmental Protection Agency (“EPA”) proposed to add microplastics as a priority contaminant group to the Drinking Water Contaminant Candidate List 6 (“CCL 6”) under the Safe Drinking Water Act. The same day, the U.S. Department of Health and Human Services (HHS) launched the Systematic Targeting Of MicroPlastics (STOMP) program, committing $144 million to measure, study, and develop methods to remove microplastics and nanoplastics from the human body. EPA tied both moves directly to the Trump administration’s “Make America Healthy Again” (“MAHA”) agenda. The comment period on the draft CCL 6 closes June 5, 2026.

The CCL 6 designation does not impose any compliance obligations today. But the history of chemical regulation teaches a consistent lesson: once an agency formally signals that a substance warrants scientific attention and possible future action, the downstream effects — on rulemaking priorities, litigation narratives, plaintiff recruitment, and investor scrutiny — can arrive long before any enforceable rule does.

A Meaningful Shift in Framing

For years, microplastics discussions were housed in debates about recycling, packaging, and marine litter. The MAHA framework has reoriented that conversation. In The MAHA Report issued by the White House in 2025, microplastics were identified alongside PFAS (per- and polyfluoroalkyl substances) as cumulative-exposure concerns affecting children’s health. EPA’s CCL 6 listing places microplastics in the same federal pipeline through which prior drinking water standards for PFAS, arsenic, and lead ultimately traveled. The PFAS trajectory is instructive: perfluorooctanoic acid (PFOA) was first listed on CCL 3 in 2008 (finalized in 2009) and took sixteen years to become an enforceable maximum contaminant level. For microplastics, that clock started April 2, 2026. A further near-term risk: the CCL feeds the Unregulated Contaminants Monitoring Rule (UCMR), which can require public water systems to monitor for listed substances — generating national occurrence data that could accelerate both regulation and plaintiff discovery.

The Litigation Landscape Is Already Moving

Microplastics litigation is still early-stage, but the trend lines are clear. Claims have generally fallen into two categories: public nuisance suits, brought primarily by state and local governments; and consumer protection suits, alleging that recycling claims, “BPA-Free” labels, or safe-disposal representations were false because products degrade into microplastics. Several cases are already pending — including suits by the City of Baltimore against major beverage companies and by California against a major plastic polymer manufacturer. No case has yet established specific human health injuries caused by microplastics, but EPA’s CCL 6 designation and HHS’s STOMP program are designed — over time — to narrow exactly that gap.

Why Agency Framing Matters to Litigation

The most important near-term consequence of the April 2026 actions may not be regulatory at all. Once a federal agency formally identifies a substance as a potential public health threat — even in a research-focused posture — that designation becomes a building block in private litigation. Plaintiffs cite agency listings to establish notice, use official exposure assessments to clear admissibility thresholds for expert testimony, and invoke agency characterizations to argue that defendants failed to act when warning signs were present. Plaintiffs will cite the CCL 6 listing as evidence of recognized public health concern and will argue that companies which failed to investigate or disclose microplastics risks after April 2026 did so against a backdrop of clear federal warning. Microplastics concerns now also enjoy unusual bipartisan political durability — from environmental advocates to MAHA-aligned public health voices — reducing the likelihood this issue will recede with a change in administration.

Analogous Litigation Offers a Cautionary Tale

The PFAS story is the most relevant analogue. Despite sustained challenges to causation theories, DuPont de Nemours, Inc., Chemours Company, and Corteva, Inc. settled for a combined $1.185 billion, and 3M separately committed between $10.5 and $12.5 billion to resolve claims in the same multidistrict litigation.¹That litigation gained momentum years before any enforceable federal standard existed. Talcum powder and climate change cases reinforce the same lesson: once litigation achieves scale, it becomes extraordinarily expensive and disruptive regardless of how the underlying science ultimately resolves.

How Companies Should Prepare

Companies across the plastics and chemicals value chain should act now. Key priorities include: reviewing internal records under privilege for consistency between prior microplastics assessments and external statements; auditing trade group positions that could be used to allege coordinated concealment; developing a coordinated communications strategy across investor disclosures and product marketing; and engaging the board to document appropriate oversight. The June 5, 2026 CCL 6 comment deadline presents an immediate opportunity to engage — companies with relevant data should submit comments that inform EPA’s scientific process and help shape the evidentiary record.

The Bottom Line

Sweeping federal microplastics restrictions are not imminent. But the April 2026 actions confirm that microplastics have moved from the margins of the federal policy agenda to its center — driven by scientific concern, political momentum, and a presidential initiative with unusual bipartisan support. For companies across the plastics value chain, the window to get ahead of this issue is open, but narrowing.

¹Both settlements resolved PFAS drinking water claims in the AFFF multidistrict litigation (MDL No. 2:18-mn-2873, D.S.C.). The DuPont/Chemours/Corteva settlement was allocated per a binding MOU; the 3M settlement, with a present value of approximately $10.3 billion, is payable over 13 years. Both received final court approval in early 2024. See DuPont Form 8-K (June 2, 2023); 3M Investor Press Release (Apr. 1, 2024).

This information is provided by Vinson & Elkins LLP for educational and informational purposes only and is not intended, nor should it be construed, as legal advice.